PYC Therapeutics (Australia) Performance
| PYC Stock | 1.40 0.05 3.45% |
The company owns a Beta (Systematic Risk) of -0.18, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning PYC Therapeutics are expected to decrease at a much lower rate. During the bear market, PYC Therapeutics is likely to outperform the market. At this point, PYC Therapeutics has a negative expected return of -0.32%. Please make sure to check PYC Therapeutics' jensen alpha, treynor ratio, and the relationship between the standard deviation and total risk alpha , to decide if PYC Therapeutics performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PYC Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:10 | Last Split Date 2024-11-15 |
1 | Insider Stock Buying Of PYC Therapeutics Delivers Return On AU5.25m Investment - Yahoo Finance | 10/28/2024 |
2 | PYC Therapeutics Announces Security Consolidation Plan - MSN | 11/20/2024 |
3 | PYC Therapeutics Announces Share Consolidation Impact - TipRanks | 11/26/2024 |
| Begin Period Cash Flow | 15.6 M |
PYC |
PYC Therapeutics Relative Risk vs. Return Landscape
If you would invest 180.00 in PYC Therapeutics on September 27, 2024 and sell it today you would lose (40.00) from holding PYC Therapeutics or give up 22.22% of portfolio value over 90 days. PYC Therapeutics is producing return of less than zero assuming 3.8399% volatility of returns over the 90 days investment horizon. Simply put, 34% of all stocks have less volatile historical return distribution than PYC Therapeutics, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
PYC Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PYC Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PYC Therapeutics, and traders can use it to determine the average amount a PYC Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.083
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PYC |
Estimated Market Risk
| 3.84 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PYC Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PYC Therapeutics by adding PYC Therapeutics to a well-diversified portfolio.
PYC Therapeutics Fundamentals Growth
PYC Stock prices reflect investors' perceptions of the future prospects and financial health of PYC Therapeutics, and PYC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PYC Stock performance.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.78) % | ||||
| Current Valuation | 587.49 M | ||||
| Shares Outstanding | 466.61 M | ||||
| Price To Book | 8.12 X | ||||
| Price To Sales | 29.61 X | ||||
| Revenue | 22.06 M | ||||
| Gross Profit | 15.81 M | ||||
| EBITDA | (38.12 M) | ||||
| Net Income | (37.73 M) | ||||
| Cash And Equivalents | 15.57 M | ||||
| Total Debt | 1.11 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (38.59 M) | ||||
| Earnings Per Share | (0.10) X | ||||
| Total Asset | 91.24 M | ||||
| Retained Earnings | (155.89 M) | ||||
About PYC Therapeutics Performance
Assessing PYC Therapeutics' fundamental ratios provides investors with valuable insights into PYC Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the PYC Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
PYC Therapeutics is entity of Australia. It is traded as Stock on AU exchange.Things to note about PYC Therapeutics performance evaluation
Checking the ongoing alerts about PYC Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PYC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PYC Therapeutics generated a negative expected return over the last 90 days | |
| PYC Therapeutics may become a speculative penny stock | |
| PYC Therapeutics has high historical volatility and very poor performance | |
| PYC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.06 M. Net Loss for the year was (37.73 M) with profit before overhead, payroll, taxes, and interest of 15.81 M. | |
| PYC Therapeutics has accumulated about 15.57 M in cash with (38.59 M) of positive cash flow from operations. | |
| Roughly 59.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing PYC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PYC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining PYC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PYC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of PYC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PYC Therapeutics' stock. These opinions can provide insight into PYC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.